| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3892 | Oleracein E | Potent antioxidant and neuroprotectant for treatment of Parkinson's disease, reducing reactive oxygen species (ROS) levels, inhibiting extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, reducing rotenone-induced up-regulation of the proapopt |
|
| DCC3893 | Olfr895-agonist-10 | Novel specific agonist of odorant receptor 895 (Olfr895) |
|
| DCC3894 | Olmutinib Hydrochloride | Novel Bruton's tyrosine kinase inhibitor, suppressing B cell and monocyte activation and ameliorates arthritis in a mouse model |
|
| DCC3895 | Olprinone | Phosphodiesterase III inhibitor, augmenting cerebral blood flow by a direct vasodilator effect on cerebral arteries |
|
| DCC3896 | Omdm-188 | Novel potent DAGL inhibitor, inhibiting collagen-, but not arachidonic acid-induced aggregation and TxA2 synthesis |
|
| DCC3897 | On012380 | Non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I |
|
| DCC3898 | Oncrasin-72 | Potent analogue of oncrasin-1 with antitumor activity mediated by JNK activation and STAT3 inhibition |
|
| DCC3899 | Ono12380 | Novel non-ATP-competitive inhibitor of BCR-ABL, overriding imatinib resistance |
|
| DCC3900 | Ono-2910 | Novel enhancer of Schwann cell differentiation for treatment of peripheral nerve disorder |
|
| DCC3901 | Ono-3307 | Protease inhibitor |
|
| DCC3902 | Ono-4007 | Lipid A analog, inducing Th1-type immune response in tumor eradication and restoring nitric oxide production by peritoneal macrophages |
|
| DCC3903 | Ono-4310321 | Potent, orally available dual CysLT1 and CysLT2 receptor antagonist |
|
| DCC3904 | Ono-ae1-259 | Highly selective agonist of prostaglandin E2 receptor (EP2) |
|
| DCC3905 | Ono-ae1-259 Lysine | Novel selective EP2 receptor agonist, inducing relaxation of smooth muscle |
|
| DCC3906 | Ono-ae1-329 | Novel agonist of the prostaglandin PGE2 receptor EP4 |
|
| DCC3907 | Ono-ae2-227 | EP(4)-selective antagonist |
|
| DCC3908 | Ono-ae-248 | Novel selective EP3 receptor agonist |
|
| DCC3909 | Ono-ae3-237 | Potent, selective, and orally active prostaglandin D2 receptor antagonist |
|
| DCC3910 | Oopz-23-l(nle)aq | Novel potent inhibitor of protein-protein interactions |
|
| DCC3911 | Opc-13213 | Metabolite of Cilostazol |
|
| DCC3912 | Opc-14117 | Antioxidant and free radical scavenger, attenuating edema formation, and subsequent tissue damage following cortical contusion |
|
| DCC3913 | Ophiobolin A | Inhibitor of calmodulin action in calcium regulation |
|
| DCC3914 | Optoglunam4.1 | Novel negative allosteric modulator (NAM) of mGlu4, being isomerized with blue-light/dark cycles with fast relaxation |
|
| DCC3915 | Orc-13661 Hydrochloride | Novel Potent, Well Tolerated, and Orally Active Protective Agent against Aminoglycoside-Induced Hearing Loss |
|
| DCC3916 | Orcein | Collagen immunostain |
|
| DCC3917 | Orex-1019 | Novel mixed κ/μ receptor antagonist. having therapeutic potential for the treatment of depression and other stress-induced conditions |
|
| DCC3918 | Org-27759 | Negative allosteric modulator at the CB1 receptor |
|
| DCC3919 | Org-29647 | CB1 allosteric modulator |
|
| DCC3920 | Org48762-0 | Selective p38alpha and p38beta kinase inhibitor |
|
| DCC3921 | Oritavancin | Lipoglycopeptide Antibacterial, acting as a inhibitor of Cytochrome P450 2C19/2C9, and a inducer of Cytochrome P450 3A4/2D6 |
|
